The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis

References

• Gatto L, Prati F. Subclinical atherosclerosis: how and when to treat it? Eur Heart J Suppl. 2020;22(Suppl. E):1–13. doi: 10.1093/eurheartj/suaa068.
   Web of Science ®Google Scholar
• Lefkou E, Fragakis N, Ioannidou E, et al. Increased levels of proinflammatory cytokines in children with family history of coronary artery disease. Clin Cardiol. 2010;33(4):E6–E10.
   Google Scholar
• Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis. J Am Coll Cardiol. 2009;54(23):2129–2138. doi: 10.1016/j.jacc.2009.09.009.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Sherer Y, Harats D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001;22(6):293–295. doi: 10.1016/s1471-4906(01)01922-6.
   PubMedGoogle Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10. doi: 10.1007/s11883-011-0219-7.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Fragakis N, Rizzo M. The therapeutic role of SGLT-2 inhibitors in acute heart failure: from pathophysiologic mechanisms to clinical evidence with pooled analysis of relevant studies across safety and efficacy endpoints of interest. Life. 2022;12(12):2062. doi: 10.3390/life12122062.
   PubMedGoogle Scholar
• Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. 2016;134(10):752–772. doi: 10.1161/CIRCULATIONAHA.116.021887.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis. 2015;241(2):507–532. doi: 10.1016/j.atherosclerosis.2015.05.007.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
   PubMed Web of Science ®Google Scholar
• Mitchell GF, Hwang S-J, Vasan RS, et al. Arterial stiffness and cardiovascular events. Circulation. 2010;121(4):505–511. doi: 10.1161/CIRCULATIONAHA.109.886655.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236–1241. doi: 10.1161/01.hyp.37.5.1236.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. J Am Coll Cardiol. 2010;55(13):1318–1327. doi: 10.1016/j.jacc.2009.10.061.
   PubMed Web of Science ®Google Scholar
• Giglio RV, Patti AM, Rizvi AA, et al. Advances in the pharmacological management of diabetic nephropathy: a 2022 international update. Biomedicines. 2023;11(2):291. doi: 10.3390/biomedicines11020291.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783–794. doi: 10.1111/dom.12670.
   PubMed Web of Science ®Google Scholar
• Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2016;24(1);73–79.
   Google Scholar
• Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail. 2019;7(2):169–172. doi: 10.1016/j.jchf.2018.11.013.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi: 10.1093/eurheartj/ehz486.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi: 10.2337/dci19-0066.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: executive summary. J Am Coll Cardiol. 2022;79(17):1757–1780. doi: 10.1016/j.jacc.2021.12.011.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–767. doi: 10.1016/S0140-6736(22)01429-5.
   PubMed Web of Science ®Google Scholar
• Baigent C, Emberson JR, Haynes R, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–1801. doi: 10.1016/S0140-6736(22)02074-8.
   PubMed Web of Science ®Google Scholar
• Kang Y, Zhan F, He M, et al. Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis. Vascul Pharmacol. 2020;133–134:106779. doi: 10.1016/j.vph.2020.106779.
   PubMed Web of Science ®Google Scholar
• Idzkowska E, Eljaszewicz A, Miklasz P, et al. The role of different monocyte subsets in the pathogenesis of atherosclerosis and acute coronary syndromes. Scand J Immunol. 2015;82(3):163–173. doi: 10.1111/sji.12314.
   PubMed Web of Science ®Google Scholar
• Baldrighi M, Mallat Z, Li X. NLRP3 inflammasome pathways in atherosclerosis. Atherosclerosis. 2017;267:127–138. doi: 10.1016/j.atherosclerosis.2017.10.027.
   PubMed Web of Science ®Google Scholar
• Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a Western diet. Diabetologia. 2017;60(2):364–376. doi: 10.1007/s00125-016-4158-2.
   PubMed Web of Science ®Google Scholar
• Nakatsu Y, Kokubo H, Bumdelger B, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017;18(8):1704. doi: 10.3390/ijms18081704.
   PubMed Web of Science ®Google Scholar
• Nasiri-Ansari Ν, Dimitriadis GK, Agrogiannis G, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106. doi: 10.1186/s12933-018-0749-1.
   PubMedGoogle Scholar
• Kim SR, Lee S-G, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127. doi: 10.1038/s41467-020-15983-6.
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl. 1):III27–III32. doi: 10.1161/01.CIR.0000131515.03336.f8.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gong D, Li S, et al. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012;223(1):78–85. doi: 10.1016/j.atherosclerosis.2012.01.031.
   PubMed Web of Science ®Google Scholar
• Barraclough JY, Patel S, Yu J, et al. The role of sodium glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease: a narrative review of potential mechanisms. Cells. 2021;10(10):2699. doi: 10.3390/cells10102699.
   PubMed Web of Science ®Google Scholar
• Durante W, Behnammanesh G, Peyton KJ. Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int J Mol Sci. 2021;22(16):8786. doi: 10.3390/ijms22168786.
   PubMed Web of Science ®Google Scholar
• Dhananjayan R, Koundinya KSS, Malati T, et al. Endothelial dysfunction in type 2 diabetes mellitus. Indian J Clin Biochem. 2016;31(4):372–379. doi: 10.1007/s12291-015-0516-y.
   PubMed Web of Science ®Google Scholar
• Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15(1):64–73. doi: 10.1177/1479164117733626.
   PubMed Web of Science ®Google Scholar
• El-Daly M, Pulakazhi Venu VK, Saifeddine M, et al. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. Vascul Pharmacol. 2018;109:56–71. doi: 10.1016/j.vph.2018.06.006.
   PubMed Web of Science ®Google Scholar
• Adingupu DD, Göpel SO, Grönros J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice. Cardiovasc Diabetol. 2019;18(1):16. doi: 10.1186/s12933-019-0820-6.
   PubMedGoogle Scholar
• Sukhanov S, Higashi Y, Yoshida T, et al. The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/caspase-1-dependent IL-1β and IL-18 secretion. Cell Signal. 2021;77:109825. doi: 10.1016/j.cellsig.2020.109825.
   PubMed Web of Science ®Google Scholar
• Li H, Shin SE, Seo MS, et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sci. 2018;197:46–55. doi: 10.1016/j.lfs.2018.01.032.
   PubMed Web of Science ®Google Scholar
• Badacz R, Przewłocki T, Legutko J, et al. microRNAs associated with carotid plaque development and vulnerability: the clinician’s perspective. Int J Mol Sci. 2022;23(24):15645. doi: 10.3390/ijms232415645.
   PubMed Web of Science ®Google Scholar
• Kabłak-Ziembicka A, Badacz R, Przewłocki T. Clinical application of serum microRNAs in atherosclerotic coronary artery disease. J Clin Med. 2022;11(22):6849. doi: 10.3390/jcm11226849.
   PubMed Web of Science ®Google Scholar
• Pignatelli P, Baratta F, Buzzetti R, et al. The sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce platelet activation and thrombus formation by lowering NOX2-Related oxidative stress: a pilot study. Antioxidants. 2022;11(10):1878. doi: 10.3390/antiox11101878.
   Web of Science ®Google Scholar
• Shen Y, Cheng L, Xu M, et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis. Metabolism. 2023;146:155657. doi: 10.1016/j.metabol.2023.155657.
   PubMed Web of Science ®Google Scholar
• Mone P, Lombardi A, Kansakar U, et al. Empagliflozin improves the microRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes. J Pharmacol Exp Ther. 2023;384(1):116–122. doi: 10.1124/jpet.121.001251.
   PubMed Web of Science ®Google Scholar
• Hattori S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr. 2018;10(1):93. doi: 10.1186/s13098-018-0395-5.
   PubMedGoogle Scholar
• Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLOS One. 2016;11(11):e0166125. doi: 10.1371/journal.pone.0166125.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu L, Yuan L, et al. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes. Diabet Med. 2016;33(12):1732–1736. doi: 10.1111/dme.13107.
   PubMed Web of Science ®Google Scholar
• Pahud de Mortanges A, Salvador DJr., Laimer M, et al. The role of SGLT2 inhibitors in atherosclerosis: a narrative mini-review. Front Pharmacol. 2021;12:751214. doi: 10.3389/fphar.2021.751214.
   PubMed Web of Science ®Google Scholar
• Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020;96(1133):156–161. doi: 10.1136/postgradmedj-2019-137186.
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11(2):79–88. doi: 10.1111/j.1463-1326.2008.00982.x.
   PubMed Web of Science ®Google Scholar
• Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus. Circulation. 2016;133(24):2459–2502. doi: 10.1161/CIRCULATIONAHA.116.022194.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sata M, Okada Y, et al. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):165–172. doi: 10.1093/ehjcvp/pvac059.
   PubMed Web of Science ®Google Scholar
• Katakami N, Mita T, Maeda N, et al. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial. Cardiovasc Diabetol. 2022;21(1):19. doi: 10.1186/s12933-022-01451-6.
   PubMed Web of Science ®Google Scholar
• Katakami N, Mita T, Yoshii H, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;22(1):143. doi: 10.1186/s12933-020-01079-4.
   Google Scholar
• Ardahanli İ. Empagliflozin may regresses carotid intima-media thickness and epicardial adipose tissue volume in patients with type 2 diabetes mellitus. Lokman Hekim Health Sci. 2021;1(3):74–80. doi: 10.14744/lhhs.2021.80001.
   Google Scholar
• Nomiyama T, Shimono D, Horikawa T, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J. 2018;65(8):859–867. doi: 10.1507/endocrj.EJ18-0022.
   PubMed Web of Science ®Google Scholar
• Irace C, Casciaro F, Scavelli FB, et al. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovasc Diabetol. 2018;17(1):52. doi: 10.1186/s12933-018-0695-y.
   PubMedGoogle Scholar
• Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84. doi: 10.1186/s12933-017-0564-0.
   PubMedGoogle Scholar
• Kishimoto S, Higashi Y, Imai T, et al. Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study. Cardiovasc Diabetol. 2023;22(1):119. doi: 10.1186/s12933-023-01856-x.
   PubMed Web of Science ®Google Scholar
• Sposito AC, Breder I, Soares AAS, et al. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol. 2021;20(1):74. doi: 10.1186/s12933-021-01264-z.
   PubMed Web of Science ®Google Scholar
• Zainordin NA, Hatta SFWM, Mohamed Shah FZ, et al. Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED). J Endocr Soc. 2020;4(1):bvz017.
   PubMed Web of Science ®Google Scholar
• Sposito AC, Breder I, Barreto J, et al. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovasc Diabetol. 2022;21(1):147. doi: 10.1186/s12933-022-01584-8.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Shimabukuro M, Machii N, et al. Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial. Diabetes Care. 2019;42(10):e159–e161. doi: 10.2337/dc19-1177.
   PubMed Web of Science ®Google Scholar
• Wei R, Wang W, Pan Q, et al. Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol. 2022;13:826604. doi: 10.3389/fendo.2022.826604.
   PubMed Web of Science ®Google Scholar
• Wu Q-L, Zheng T, Li S-Z, et al. Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2022;14(1):41. doi: 10.1186/s13098-022-00810-3.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Papadopoulos C, Zografou I, et al. Effect of empagliflozin and dapagliflozin on ambulatory arterial stiffness in patients with type 2 diabetes mellitus and cardiovascular co-morbidities: a prospective, observational study. Medicina. 2022;58(9):1167. doi: 10.3390/medicina58091167.
   PubMedGoogle Scholar
• Katakami N, Mita T, Yoshii H, et al. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. Cardiovasc Diabetol. 2021;20(1):4. doi: 10.1186/s12933-020-01206-1.
   PubMed Web of Science ®Google Scholar
• Kourtidou C, Rafailidis V, Varouktsi G, et al. Effects of sodium-glucose co-transporter-2 inhibitors on markers of vascular damage. J Pers Med. 2023;13(3):536. doi: 10.3390/jpm13030536.
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Fountoulakis N, Stathi D, et al. Does dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial. Front Cardiovasc Med. 2022;9:992327. doi: 10.3389/fcvm.2022.992327.
   PubMed Web of Science ®Google Scholar
• Bosch A, Ott C, Jung S, et al. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44. doi: 10.1186/s12933-019-0839-8.
   PubMedGoogle Scholar
• Papadopoulou E, Loutradis C, Tzatzagou G, et al. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. J Hypertens. 2021;39(4):749–758. doi: 10.1097/HJH.0000000000002690.
   PubMed Web of Science ®Google Scholar
• Hong J-Y, Park K-Y, Kim J-D, et al. Effects of 6 months of dapagliflozin treatment on metabolic profile and endothelial cell dysfunction for obese type 2 diabetes mellitus patients without atherosclerotic cardiovascular disease. J Obes Metab Syndr. 2020;29(3):215–221. doi: 10.7570/jomes20040.
   PubMed Web of Science ®Google Scholar
• Hidalgo Santiago JC, Maraver Delgado J, Cayón Blanco M, et al. Arterial en pacientes con diabetes mellitus tipo 2. Med Clin. 2020;154(5):171–174. doi: 10.1016/j.medcli.2019.05.028.
   PubMedGoogle Scholar
• Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138. doi: 10.1186/s12933-017-0621-8.
   PubMed Web of Science ®Google Scholar
• Striepe K, Jumar A, Ott C, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136(12):1167–1169. doi: 10.1161/CIRCULATIONAHA.117.029529.
   PubMed Web of Science ®Google Scholar
• Bechlioulis A, Markozannes G, Chionidi I, et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study. J Diabetes Complications. 2023;37(4):108436. doi: 10.1016/j.jdiacomp.2023.108436.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Papadopoulos C, Kassimis G, et al. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. Vasc Med. 2022;27(5):433–439. doi: 10.1177/1358863X221101653.
   PubMed Web of Science ®Google Scholar
• Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J. 2007;153(6):907–917. doi: 10.1016/j.ahj.2007.03.019.
   PubMed Web of Science ®Google Scholar
• Mahabadi AA, Lehmann N, Kälsch H, et al. Association of epicardial adipose tissue with progression of coronary artery calcification Is more pronounced in the early phase of atherosclerosis. JACC Cardiovasc Imaging. 2014;7(9):909–916. doi: 10.1016/j.jcmg.2014.07.002.
   PubMed Web of Science ®Google Scholar
• Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample. Circulation. 2008;117(5):605–613. doi: 10.1161/CIRCULATIONAHA.107.743062.
   PubMed Web of Science ®Google Scholar
• Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF. JACC Heart Fail. 2021;9(8):578–589. doi: 10.1016/j.jchf.2021.04.014.
   PubMed Web of Science ®Google Scholar
• Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20(1):32. doi: 10.1186/s12933-021-01228-3.
   PubMed Web of Science ®Google Scholar
• Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. doi: 10.1186/s12933-017-0658-8.
   PubMedGoogle Scholar
• Yagi S, Hirata Y, Ise T, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9(1):78. doi: 10.1186/s13098-017-0275-4.
   PubMedGoogle Scholar
• Bouchi R, Terashima M, Sasahara Y, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16(1):32. doi: 10.1186/s12933-017-0516-8.
   PubMedGoogle Scholar
• Fukuda T, Bouchi R, Terashima M, et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther. 2017;8(4):851–861. doi: 10.1007/s13300-017-0279-y.
   PubMed Web of Science ®Google Scholar
• Myasoedova VA, Parisi V, Moschetta D, et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):23. doi: 10.1186/s12933-023-01738-2.
   PubMed Web of Science ®Google Scholar